Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Livzon Pharmaceutical Group ( (HK:1513) ).
Livzon Pharmaceutical Group has updated the terms of reference for its Nomination Committee under the Board, effective May 22, 2025. The Committee will consist of at least three members, primarily independent non-executive directors, with a focus on gender diversity. The changes align with the listing requirements of the Hong Kong and Shenzhen stock exchanges, potentially enhancing governance and stakeholder confidence.
The most recent analyst rating on (HK:1513) stock is a Sell with a HK$24.00 price target. To see the full list of analyst forecasts on Livzon Pharmaceutical Group stock, see the HK:1513 Stock Forecast page.
More about Livzon Pharmaceutical Group
Livzon Pharmaceutical Group Inc. operates in the pharmaceutical industry, focusing on the development, production, and sale of pharmaceutical products. The company is listed on the Hong Kong and Shenzhen stock exchanges, adhering to their respective listing rules.
Average Trading Volume: 1,090,004
Technical Sentiment Signal: Buy
Current Market Cap: HK$31.19B
For a thorough assessment of 1513 stock, go to TipRanks’ Stock Analysis page.